MSc in Experimental and Translational Therapeutics
Oxford has made a major contribution to modern molecular medicine and our senior scientists have provided significant insights to our understanding of cancer, diabetes, and cardiac, haematological and infectious diseases. There is now an opportunity to harness these advances and translate them into therapeutic benefits for patients.
The Department of Oncology and the Department for Continuing Education offer a part-time MSc in Experimental and Translational Therapeutics that brings together some of Oxford's leading clinicians and scientists to deliver an advanced modular programme designed for those in full-time employment, both in the UK and overseas.
The Programme draws on the world-class research and teaching in experimental therapeutics at Oxford University and offers a unique opportunity to gain an understanding of the principles that underpin clinical research and to translate this into good clinical and research practice.
Online info session
We recently held an online information session and Q&A, in which participants gained a brief overview of the course, met the course team and had the opportunity to ask questions. Please subscribe to our emails to be notified of future events.
- Programme details
- Course aims
- Oxford college affiliation
- Teaching staff
- Resources available
- IT requirements
- Entry requirements
- Fees and funding
- When to apply
- How to apply
- Pharmaceutical Medicine Specialty Training (PMST)
The MSc in Experimental and Translational Therapeutics consists of six modules and a research project and dissertation. The programme is normally completed in two to three years. Students are full members of the University of Oxford and are matriculated as members of an Oxford college.
The modules in this programme can also be taken as individual short courses. It is possible to transfer credit from up to three previously completed modules into the MSc programme, if the time elapsed between commencement of the accredited module(s) and registration on the MSc is not more than two years.
The programme modules are listed below. The dates shown on the module websites are for the academic year 2023-2024. The dates for the modules in the 2024-25 academic year will be updated in due course:
- The Structure of Clinical Trials and Experimental Therapeutics
- Drug Development, Pharmacokinetics and Imaging
- Pharmacodynamics, Biomarkers and Personalised Therapy
- Adverse Drug Reactions, Drug Interactions, and Pharmacovigilance
- How to do Research on Therapeutic Interventions: Protocol Preparation
- Biological Therapeutics
The course will appeal to health professionals from a wide range of backgrounds, including:
- qualified doctors
- specialist registrars in clinical pharmacology or in training for other medical sub-specialities
- clinical research fellows
- graduates working in the pharmaceutical industry or in academic clinical trials
The class-based modules will include a period of preparatory study, a week of intensive face-to-face lectures and tutorials, followed by a period for assignment work. Attendance at modules will be a requirement for study. Some non-classroom activities may be provided at laboratory facilities elsewhere in the University. The course will include taught material on research skills. A virtual learning environment (VLE) will provide between-module support.
The taught modules will include group work, discussions, guest lectures, and interaction and feedback with tutors and lecturers. Practical work aims to develop the students' knowledge and understanding of the subject.
The aim of the MSc programme is to provide students with the necessary training and practical experience to enable them to understand the principles that underpin clinical research, and to enable them to translate that understanding into good clinical and research practice.
By the end of the MSc programme, students should gain an understanding of the following core principles:
- How drugs are developed and marketed
- Pharmacokinetics and drug metabolism
- The use of non-invasive imaging in drug development
- How to design phase I, II and III clinical trials for a range of novel therapeutic interventions
- The pharmacodynamic factors that affect drug therapy
- Interindividual differences in the clinical population and stratified medicine
- Biomarkers and laboratory assays used to support trial end-points
- Adverse drug reactions, drug interactions, and pharmacovigilance
- The important aspects of drug regulation
- Ethical issues of clinical trial participation
- Current cutting-edge research into novel biological therapeutics
- Application of statistics to medicine
By the end of the programme, students should be equipped to:
- demonstrate a knowledge of the principles, methods and techniques for solving clinical research problems and translate this into good clinical and research practice
- apply skills gained in techniques and practical experience from across the medical and biological sciences
- develop skills in managing research-based work in experimental therapeutics
- carry out an extended research project involving a literature review, problem specification and analysis in experimental therapeutics and write a short dissertation
As a matriculated postgraduate degree student, you will become a member of one of the University’s famous interdisciplinary colleges, enabling you to encounter new perspectives in your field or learn more about many other different subjects from fellow college members.
The collegiate system makes studying at Oxford a truly special experience. Oxford colleges are small, intimate communities, where you could find yourself absorbed in fascinating conversations with students and academics from a variety of disciplines at college seminars, dinners, and informal occasions.
To find out more about Oxford University colleges, please consult the University's Graduate Admissions website.
Professor Leonard Seymour
Role: Course Director & Tutor
Module Lead of Biological Therapeutics module
Professor Seymour is a world authority on genetic medicine, with over 200 publications and several patents. Len is Professor of Gene Therapies, and Director of the Section of Clinical Pharmacology at the University of Oxford’s Department of Oncology.
Len sits on a number of editorial and scientific advisory boards, was the founding President of the British Society for Gene Therapy, and is a board member of the International Society for Cell and Gene Therapy of Cancer. He is also Co-Founder of Psioxus Therapeutics Ltd, The Native Antigen Company Ltd and Oxford Genetics.
Dr Elaine Johnstone
Role: Deputy Course Director & Tutor
Module Lead of Pharmacodynamics, Biomarkers and Personalised Therapy module
Dr Elaine Johnstone is a Translational Research Scientist with a BSc in Medicinal Chemistry, an MSc in Molecular Pathology and Toxicology and a PhD in Molecular Pharmacology. Her PhD at the Cancer Research Unit, University of Newcastle upon Tyne, was the seed of the start of a career researching drug pharmacology, pharmacodynamics and personalised/precision medicine. After a fellowship studying differential drug response in sarcoma at the University of Bordeaux, her Oxford career initially focussed on cancer prevention, via optimising smoking cessation therapies.
She has more recently focussed on studying biomarkers of prognosis and of treatment effectiveness within clinical trials (predominantly colorectal cancer) in the Department of Oncology.
With more than 20 years of experience in translational research and 50+ publications in the area, Elaine is the lead tutor on Module 3 and also the Deputy Course Director.
Professor Rachel Kerr
Module Lead of The Structure of Clinical Trials and Experimental Therapeutics module.
Professor Kerr gained a BSc (Physiology) followed by an MBChB with Honours from University of Birmingham in 1994. After general medical postgraduate training (MRCP) she undertook research into cancer vaccines, leading to the award of her PhD in 2002.
Rachel is Associate Professor of Gastrointestinal Oncology in the Department of Oncology at the University of Oxford and Consultant Medical Oncologist at Oxford University Hospitals NHS Trust within the colorectal cancer multidisciplinary team.
She has been the recipient of multiple personal fellowships from the MRC, DH and HEFCE and has authored over 100 papers in the field of colorectal cancer. Rachel is also Clinical Director of Phase 3 Trials at the Oncology Clinical Trials Office (OCTO) based within the University and has extensive experiencing setting up, managing and writing up clinical trials in this area. Rachel has been CI / Co-CI on trials that have recruited almost 15,000 patients over the last 15 years.
Dr Emma Mead
Module Lead of Drug Development, Pharmacokinetics and Imaging module.
Emma received her PhD in Neuroscience from University College London, investigating the role of reactive oxygen species in modulating neuroinflammation in Alzheimer’s disease. Following a post-doctoral research position at Cardiff University, where she studied the mechanism of action of naturally occurring anti-inflammatory compounds, Emma joined Eli Lilly as a senior scientist and team co-ordinator. Emma worked in target validation and early drug discovery for neurodegeneration, and established an in vitro neuroinflammation assay platform. Emma now leads the neuroinflammation team at the ODDI, who utilise human iPSC macrophage and primary microglial cultures for target validation, and develop cell based screening assays for progression of neuroinflammatory projects.
Dr Michael Theodorakis
Module Lead of Adverse Drug Reactions, Drug Interactions and Pharmacovigilance module.
Dr Michael Theodorakis is a Senior Clinical Researcher at the Diabetes Trials Unit, Oxford Centre for Diabetes Endocrinology and Metabolism, University of Oxford. He is the Clinical Lead of large scale clinical trials and Principal Investigator on early phase studies with the Translational Research Group at the Oxford Biomedical Research Centre. He is also an Honorary Consultant Physician in the Oxford University Hospitals NHS Foundation Trust.
Michael has served in the past and continues to serve as a Member of Committees at the European Medicines Agency and other EU Commission workgroups, along with his continuing membership in many prominent professional societies and scientific associations in Europe and the US.
Michael has long been involved in clinical research and has been especially active in translational research, focusing on innovative pharmacological design and development of novel compounds for human use.
Ms Susan Tonks
Module Lead of How to do Research on Therapeutic Interventions: Protocol Preparation module.
Ms Susan Tonks has a background in laboratory-based research, Research Governance, the management of large-scale clinical research and a keen interest in research ethics.
For the past 8 years Susan has been involved in the conduct, delivery and governance of research studies, largely based in the Global South. These have included STRATAA (Strategic Typhoid alliance across Africa & Asia), Typhoid Vaccine Acceleration Consortium (TyVAC), THECA (Typhoid Conjugate Vaccine Introduction in Africa) and more latterly PANDORA (PAthogeN Detection to Optimise antibiotic Regimes -Africa). She is also the GCP trial monitor for the Jenner Institute, University of Oxford.
Susan is a long-standing member and current chair of a Health Research Authority Research Ethics Committee reviewing all phases of clinical trials and other research requiring ethical approval. She also facilitates training in various topics for the Health Research Authority and National Institute for Health Research including Adults Lacking Capacity to Consent, the Declaration of Helsinki, Valid Informed Consent and Next steps in Delivering Clinical Research.
Dr Grant D Vallance
Module Lead of How to do Research on Therapeutic Interventions: Protocol Preparation module.
Dr Grant D Vallance originally hails from New Zealand. He has an undergraduate degree in Biochemistry and a Masters in Bioethics from the University of Otago. His Ph.D. is in Ethics and the Philosophy of Science and from the Open University. He has taught research ethics for almost 15 years, been involved in 5 different research ethics committees, and worked as a clinical trial coordinator in the University of Oxford & NHS.
Currently, Grant is employed in clinical informatics and information management in the NHS, and is the lead for Module 5 in the Experimental and Translational Therapeutics Programme.
University of Oxford libraries, including:
Plus facilities from the Department for Continuing Education, including:
- The Graduate School
- Canvas virtual learning environment
- Connection to wireless Internet via OWL (Oxford Wireless LAN) and/or Eduroam
This course uses the Department’s online assignment submission system. In order to prepare and submit your course assignments you will need access to the Internet and a computer meeting our recommended minimum computer specification. Students of this course may use the student computing facilities provided in Departmental buildings.
Please visit the MSc in Experimental and Translational Therapeutics page on the University of Oxford Graduate Admissions website for details of the entry requirements.
MSc fee rates for the academic year 2024/25
The fee rates listed are for the 2024/25 academic year and you should expect these to increase annually.
You will be required to pay a minimum of two annual award fees, and a further annual award fee for every additional academic year (or part-year) that you attend the course, and to pay module or dissertation fees as they become due. Fees must be paid in accordance with the Terms and Conditions (see below) for this programme. All amounts are in pounds sterling.
- Annual award fee: £2,055 for Home students / £8,455 for Overseas students (see note 1*)
- Module fee: £2,570 (per taught module)
- Dissertation fee: £7,710 (equivalent to 3 module fees)
Illustration for MSc programme (assumes completion within two years)
- 2 x annual award fee = £4,110
- 6 x module fee (6 taught modules) = £15,420
- 1 x dissertation fee = £7,710
- Total: £27,240
- 2 x annual award fee = £16,910
- 6 x module fee (6 taught modules) = £15,420
- 1 x dissertation fee = £7,710
- Total: £40,040
- The fee rates listed are for the academic year shown, and you should be aware that these rates will increase annually, so students should expect the total to be higher than is shown in the Illustration. The exact amount will depend on the fee rates set annually, and upon the years you are in attendance; these are normally published well before the start of each academic year, but for your own budgetary purposes you may wish to estimate a 5% annual increase on fee rates.
- See the Oxford University website for Home and Overseas classification of students for fees purposes.
- MSc students are matriculated and are full members of the Collegiate University; college fees are included within the MSc programme fees and are paid to the colleges on a student’s behalf
Funding and scholarships
Details of funding opportunities, including grants, bursaries, loans, scholarships and benefit information are available on our financial assistance page.
Judith Hockaday Travel Bursaries: Students attending postgraduate medical courses who are normally resident in less developed countries may be eligible for a bursary to help with travel to and from Oxford.
We strongly recommend that you apply by the January or March deadlines. After the March deadline, the course will only stay open for that year's entry if places are still available.
Remember that it can take a number of weeks to obtain all of the documents you need and prepare a competitive application. You should also allow your referees plenty of time to submit your references. We therefore recommend you apply as soon as possible.
Applications for this course should be made online via the University of Oxford Graduate Admissions website. Please see the Graduate Course Guide and the Application Guide for more information on how to apply.
Early application is strongly advised. All applications must have been fully completed before the application deadline. Shortlisted applicants will be invited to an online interview and asked to provide evidence of their funding for the programme.
Application deadlines* can be found on the MSc in Experimental and Translational Therapeutics page on the University of Oxford Graduate Admissions website.
*Applications completed before the January Deadline will automatically be considered for a Clarendon Scholarship.
Later applications may be considered if places are available.
All supporting materials, including references, need to have been received by the relevant deadline. Please contact the administrative team if you have any questions concerning the deadlines for the course.
Guidance from the UK Royal College of Physician's Faculty of Pharmaceutical Medicine
The Faculty have confirmed that if enrolled for Pharmaceutical Medicine Specialty Training (PMST), trainees may be able to use knowledge provided by Experimental and Translational Therapeutics modules to cover aspects of a module of the PMST curriculum. Trainees are advised to discuss this with their Educational Supervisor.
Experimental and Translational Therapeutics modules may also be used to provide those pursuing the Faculty's Diploma in Pharmaceutical Medicine (DPM) with the necessary knowledge required to cover the Diploma syllabus. Applicants for the DPM exam are advised to read the DPM syllabus and rules and regulations.
Members of the Faculty of Pharmaceutical Medicine who are registered in the Faculty's CPD scheme can count participation in Experimental and Translational Therapeutics modules towards their CPD record. Non-members may wish to obtain further advice about CPD credit from their Royal College or Faculty.